Viridian Therapeutics, Inc. (NASDAQ:VRDN) Position Boosted by Vanguard Group Inc.

Vanguard Group Inc. boosted its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 4.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,595,049 shares of the company's stock after purchasing an additional 174,952 shares during the quarter. Vanguard Group Inc. owned approximately 5.80% of Viridian Therapeutics worth $88,087,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its position in shares of Viridian Therapeutics by 5.8% during the third quarter. Geode Capital Management LLC now owns 1,493,311 shares of the company's stock worth $33,979,000 after acquiring an additional 81,951 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Viridian Therapeutics by 11.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 575,070 shares of the company's stock valued at $11,024,000 after purchasing an additional 58,857 shares during the period. Fisher Asset Management LLC grew its position in Viridian Therapeutics by 4.7% in the 4th quarter. Fisher Asset Management LLC now owns 518,027 shares of the company's stock worth $9,931,000 after purchasing an additional 23,103 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Viridian Therapeutics in the fourth quarter valued at approximately $7,868,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of Viridian Therapeutics by 218.5% during the third quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company's stock valued at $9,108,000 after buying an additional 274,641 shares during the last quarter.

Analyst Ratings Changes

VRDN has been the topic of several recent analyst reports. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $27.00 target price (down previously from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Needham & Company LLC restated a "buy" rating and set a $38.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. Royal Bank of Canada upped their price objective on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a report on Tuesday, December 17th. Finally, HC Wainwright reissued a "buy" rating and set a $34.00 target price on shares of Viridian Therapeutics in a research note on Monday, December 16th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $35.70.

Viridian Therapeutics Price Performance

NASDAQ:VRDN traded down $0.15 during trading hours on Tuesday, reaching $13.15. 268,194 shares of the company's stock were exchanged, compared to its average volume of 1,190,469. The company has a market capitalization of $1.07 billion, a P/E ratio of -3.06 and a beta of 0.81. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $27.20. The business's 50-day simple moving average is $14.96 and its two-hundred day simple moving average is $18.84. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.24. The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Sell-side analysts expect that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.